Thiamine is named as an intervention in 3 current clinical trials in our France and China registers. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Shanghai Zhongshan Hospital (1). The most-studied condition is Familial Adenomatous Polyposis (FAP). The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Thiamine. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA
2025-524148-36-00 · Mental Disorders
|
Phase 2 | Authorised | Institut National De La Sante Et De La Recherche Medicale | France |
| Lead sponsor | Trials |
|---|---|
| Shanghai Zhongshan Hospital | 1 |
| Centre Hospitalier de Bethune | 1 |
| Institut National de la Santé Et de la Recherche Médicale, France | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 2 | 1 |
| Clinical trials in China | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
3 current trials in our France and China registers name Thiamine (also registered as Vitamin B1) as a drug or biological intervention, as of the registry sync on 2 October 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai Zhongshan Hospital (1), Centre Hospitalier de Bethune (1) and Institut National de la Santé Et de la Recherche Médicale, France (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Thiamine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Thiamine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Thiamine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 2 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
